Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

17.52 -0.14 (-0.82%)

Streaming Delayed Price Updated: 11:32 AM EST, Dec 26, 2025 Add to My Watchlist

Price and Volume

Volume	100,350
Open	17.70
Bid (Size)	17.49 (700)
Ask (Size)	17.54 (200)
Prev. Close	17.66
Today's Range	17.39 - 17.73
52wk Range	2.210 - 18.31
Shares Outstanding	43,614,075
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) Shows Strong Growth and Momentum Alignment with Minervini Strategy ↗

December 13, 2025

PHAT stock aligns with the Minervini growth strategy, showing a strong technical uptrend and explosive 460% revenue growth, making it a high-potential momentum candidate.

Via Chartmill

High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) ↗

November 14, 2025

Discover a powerful stock-picking strategy combining Minervini's Trend Template with High Growth Momentum to find high-potential stocks like PHAT.

Via Chartmill

Performance

YTD	+138.9%	+138.9%
1 Month	+17.3%	+17.3%
3 Month	+50.2%	+50.2%
6 Month	+83.4%	+83.4%
1 Year	+116.2%	+116.2%

More News

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

November 04, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

November 03, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance ↗

October 30, 2025

Via Chartmill

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

October 30, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

October 25, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

October 23, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

October 20, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

October 06, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 01, 2025

Via Benzinga

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

August 25, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

August 20, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom (PHAT) Q2 Revenue Jumps 441% ↗

August 07, 2025

Via The Motley Fool

Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket ↗

August 07, 2025

Via Chartmill

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 07, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

July 28, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16, 2025

From Phathom Pharmaceuticals

Via GlobeNewswire

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗

June 13, 2025

Via Benzinga

Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna ↗

June 06, 2025

Via Benzinga

Which stocks are moving on Friday? ↗

June 06, 2025

Via Chartmill

Frequently Asked Questions

Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?

Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market

What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?

The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 17.52

When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 12/26/25 11:32 AM ET

What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 763.90M

How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?

Phathom Pharmaceuticals, Inc. - Common Stock has 764M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.